REDWOOD CITY, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that data related to three of its clinical-stage programs will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9, 2015 in Boston, MA.
Among the abstracts accepted for presentation are Phase 1a data for single-agent brontictuzumab (anti-Notch1, OMP-52M51) in advanced solid tumors, including initial results from an expansion cohort of patients whose tumors demonstrate an overexpression of the activated form of Notch1 as measured by a companion biomarker. In addition, biomarker data for vantictumab (anti-Fzd7, OMP-18R5) in non-small cell lung cancer, as well as results of preclinical studies for OncoMed’s anti-DLL4/VEGF bispecific (OMP-305B83), will also be presented. Details for the presentation are provided below.
Friday, November 6, 2015
Abstract #A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer
Lead author: Ann Kapoun, Ph.D., OncoMed
Poster session A: Biomarkers
Time and location: 12:15 pm - 3:15 pm / Exhibit hall C-D
Sunday, November 8, 2015
Abstract #C42: Safety and preliminary efficacy results of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors
Lead author: Pamela Munster, M.D., University of California, San Francisco
Poster session C: Clinical Trials
Location and time: 12:30 pm - 3:30 pm / Exhibit hall C-D
Abstract #C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency
Lead author: Wang-Ching Yen, Ph.D., OncoMed
Poster session C: Therapeutic Agents: Biological
Time and location: 12:30 pm -3:30 pm / Exhibit hall C-D
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
Senior Director, Investor Relations and Corporate Communications
Source:OncoMed Pharmaceuticals, Inc.